Lytix Biopharma As
Clinical trials sponsored by Lytix Biopharma As, explained in plain language.
-
Scientists test 'Train & Attack' immune therapy for tough sarcoma
Disease control CompletedThis study tested a two-step immunotherapy for people with advanced soft tissue sarcoma that had stopped responding to standard treatments. First, a drug called LTX-315 was injected into one tumor to help attract the patient's own immune cells. Then, those immune cells were colle…
Phase: PHASE2 • Sponsor: Lytix Biopharma AS • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Direct tumor shots tested to revive immune attack on stubborn melanoma
Disease control CompletedThis study tested a new approach for patients with advanced melanoma that had stopped responding to standard immunotherapy. Doctors injected an experimental drug called LTX-315 directly into accessible tumors, while also giving the immunotherapy drug pembrolizumab. The goal was t…
Phase: PHASE2 • Sponsor: Lytix Biopharma AS • Aim: Disease control
Last updated Mar 18, 2026 18:25 UTC